Eli Lilly allies itself with Alzheimer's institute in phase III dementia drug trials

Banner Alzheimer's Institute will assist Eli Lilly in its phase III study of the company's Alzheimer's treatment, donanemab.

Photo: Mike Blake/REUTERS / X00030

Eli Lilly has announced a collaboration with Banner Alzheimer's Institute, which specializes in early identification and tracking of the disease, over a phase III trial of its drug donanemab.

Bloomberg News reports that the US pharmaceutical group was awarded breakthrough therapy status for the drug by the US Food and Drug Authority, FDA.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs